消化系统肿瘤“免疫治疗前移”的探索

doi:10.11904/j.issn.1002-3070.2021.03.012

Abstract

Abstract: The emergence of immunosuppressive checkpoint inhibitors has brought new hope for tumor treatment.Immune checkpoint inhibitors need to activate autoimmune anti-tumor cells,so immunotherapy may bring more benefits to patients when their immune status is better.At present,immunotherapy is mostly used for the posterior line treatment of tumor,but the patients after multi-line treatment are generally in poor condition,and the effect of immunotherapy may be reduced.“Immunotherapy forward” refers to the application of immunotherapy in the process of tumor treatment in order to achieve better therapeutic effects.This article reviews the background,clinical trials and problems to be solved of “immunotherapy forward” in digestive system tumors.

Key words: Digestive system tumor, Immune checkpoint inhibitors, Immunotherapy

CLC Number:

R735

MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors[J]. Journal of Practical Oncology, 2021, 35(3): 258-262.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.03.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I3/258

References

1 Mattiuzzi C,Lippi G.Current cancer epidemiology[J].J Epidemiol Glob Health,2019,9(4):217-222.
2 Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.
3 Boussiotis VA,Chatterjee P,Li L.Biochemical signaling of PD-1 on T cells and its functional implications[J].Cancer J,2014,20(4):265-271.
4 Yao S,Zhu Y,Chen L.Advances in targeting cell surface signalling molecules for immune modulation[J].Nat Rev Drug Discov,2013,12(2):130-146.
5 Keung EZ,Ukponmwan EU,Cogdill AP,et al.The rationale and emerging use of neoadjuvant immune checkpoint blockade for solid malignancies[J].Ann Surg Oncol,2018,25(7):1814-1827.
6 Reck M,Rodríguez-Abreu D,Robinson AG,et al.Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J].N Engl J Med,2016,375(19):1823-1833.
7 Altundag K.Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J].N Engl J Med,2019,380(10):986-987.
8 王程浩,韩泳涛.2020年中国临床肿瘤学会《食管癌诊疗指南》解读[J].肿瘤预防与治疗,2020,33(4):285-290.
9 Hong MH,Kim HR,Park SY,et al.A phase Ⅱ trail of preoperative chemoradiotherapy and Pembrolizumab for locally advanced esophageal squamous cell carcinoma(ESCC)[J].J Clin Oncol,2019,37(15):4027.
10 Shapiro J,van Lanschot JJB,Hulshof MCCM,et al.Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer(CROSS):long-term results of a randomised controlled trial[J].Lancet Oncol,2015,16(9):1090-1098.
11 Zhang B,Qi L,Wang X,et al.Phase 2 study of camrelizumab(anti-PD-1 antibody)combined with apatinib and chemotherapy for the first-line treatment of advanced esophageal squamous cell carcinoma[J].J Clin Oncol,2019,37(15):4033.
12 闫滢,胡冰,王刚,等.紫杉醇联合奈达铂与奈达铂联合5-氟尿嘧啶作为一线方案治疗晚期食管鳞癌的对比研究[J].安徽医药,2011,15(11):1416-1417.
13 Kato K,Shah MA,Enzinger P,et al.KEYNOTE-590:Phase III study of first-line chemotherapy with or without Pembrolizumab for advanced esophageal cancer[J].Future Oncol,2019,15(10):1057-1066.
14 Vrána D,Matzenauer M,Melichar B.Current status of checkpoint inhibitors in the treatment of esophageal and gastric tumors-overview of studies[J].Klin Onkol,2017,31(1):35-39.
15 邱海波,周志伟.NCCN胃癌临床实践指南2017年第五版更新要点解读[J].中华胃肠外科杂志,2018,21(2):160-164.
16 Bang YJ,Kang YK,Catenacci DV,et al.Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma:results from the phase II nonrandomized KEYNOTE-059 study[J].Gastric Cancer,2019,22(4):828-837.
17 Tabernero J,Van Cutsem E,Bang Y,et al.Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction(G/GEJ)adenocarcinoma:the phase 3 KEYNOTE-062 study[J].Ann Oncol,2019,30(4):152-153.
18 Wang F,Wei XL,Wang FH,et al.Safety,efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab,a PD-1 antibody in phase Ib/II clinical trial NCT02915432[J].Ann Oncol,2019,30(9):1479-1486.
19 Bang YJ,Van Cutsem E,Fuchs CS,et al.KEYNOTE-585:phase III study of perioperative chemotherapy with or without Pembrolizumab for gastric cancer[J].Future Oncol,2019,15(9):943-952.
20 陈功.2017版美国国立综合癌症网络结直肠癌指南更新解读[J].中华胃肠外科杂志,2017,20(1):28-33.
21 Lenz HJ,Van Cutsem E,Limon ML,et al.Durable clinical benefit with Nivolumab(NIVO)plus low-dose Ipilimumab(IPI)as first-line therapy in microsatellite instability-high/mismatch repair deficient(MSI-H/dMMR)metastatic colorectal cancer(mCRC)[J].Ann Oncol,2018,29(8):714.
22 Chalabi M,Fanchi LF,Dijkstra KK,et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J].Nat Med,2020,26(4):566-576.
23 Aglietta M,Barone C,Sawyer MB,et al.A phase I dose escalation trial of tremelimumab(CP-675,206)in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer[J].Ann Oncol,2014,25(9):1750-1755.
24 孟长婷.《2018年美国国立综合癌症网络胰腺癌临床实践指南(V2版)》更新要点及临床路径[J].临床肝胆病杂志,2018,34(11):2316-2323.
25 孙永琨.2018《CSCO原发性肝癌诊疗指南》解读-全身治疗部分[J].肝癌电子杂志,2018,5(3):11-14.
26 Kudo M.Extremely high objective response rate of lenvatinib:its clinical relevance and changing the treatment paradigm in hepatocellular carcinoma[J].Liver Cancer,2018,7(3):215-224.
27 Qin S,Cheng AL,Ducreux MP,et al.IMbrave150:a randomised phase III study of atezolizumab+bevacizumab vs.sorafenib in locally advanced or metastatic hepatocellular carcinoma[J].Ann Oncol,2018,29(9):66.

[1]	WANG Mengmeng, LIAN Jie, LI Hengzhen, ZHANG Yanqiao. Research progress in immunotherapy of gastrointestinal pancreatic neuroendocrine tumors [J]. Journal of Practical Oncology, 2021, 35(2): 154-159.
[2]	WANG Mingming, CHEN Xiaopin. Research progress of anti-PD-1/PD-L1 and anti-CTLA-4 immunotherapy in head and neck squamous cell carcinoma [J]. Journal of Practical Oncology, 2021, 35(2): 179-183.
[3]	LIU Xuejing,XU Yanying. Research progress of B7-H6 in malignant tumors [J]. Journal of Practical Oncology, 2021, 35(1): 46-49.
[4]	ZHANG Lu,LU Jingyu,LU Haijun. The relationship between biomarkers of head and neck squamous cell carcinoma and prognosis of immunotherapy [J]. Journal of Practical Oncology, 2021, 35(1): 55-58.
[5]	SHI Linna, SUI Hong. Progress and challenges of immune checkpoint inhibitor therapy for primary hepatocellular carcinoma [J]. Journal of Practical Oncology, 2020, 34(6): 560-564.
[6]	HOU Jianying,ZHU Wei. Research progress of immunosuppressive PD-1/PD-L1 in treatment of ovarian cancer [J]. Journal of Practical Oncology, 2020, 34(3): 266-270.
[7]	LIU Chao, ZHENG Tongsen. Summary and reflection on the medical work of oncology during the outbreak of corona virus disease 2019 [J]. Journal of Practical Oncology, 2020, 34(2): 100-102.
[8]	CAO Difei, HUANG Guoqing, XUE Jiaying, WU Qiong, WANG Lei, LI Yao. The role of CA153 in breast cancer immunotherapy [J]. Journal of Practical Oncology, 2019, 33(6): 566-569.
[9]	YAO Yang, ZHANG Yanqiao. Mechanism and recent progress of gastric cancer in immunological checkpoint inhibitors [J]. Journal of Practical Oncology, 2019, 33(4): 371-375.
[10]	HAN Bangling, WANG Yimin, XUE Yingwei. Research progress of vitamin D in tumors of digestive system [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 471-475.
[11]	SUN Zugang,WANG Zhe,CHEN Huaian,LIU Shuo,MIAO Wenlong. Progress in common chronic inflammatory factors inducing bladder cancer and its immunotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 357-361.
[12]	ZHANG Ting, JIA Di, YANG Dan. Progress in biological treatment of osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 254-257.
[13]	ZENG Yulan,LIU Yangyang,LIANG Jinyan,GU Feifei,LIU Li. Advances in drug resistance mechanism of immunological checkpoint inhibitors and post-drug resistant therapeutic strategy [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 353-358.
[14]	ZHANG Rui, WANG Zhiyu, WEN Xiaoting, ZHAO Hui. Study progresses of tumor immunosuppressive microenvironment in tumor immunotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(2): 167-171.
[15]	HUANG Juanjuan, WANG Wenxin, CAO Fenglin. Research progress of cellular immunotherapy for hematological malignancies [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 61-65.

Exploration of “immunotherapy moving forward” for digestive system tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments